Caris Life Sciences, Inc. (CAI) — Financial statements
Income statement, balance sheet, and cash flow for Caris Life Sciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 812↑97.0% | 412↑34.7% | 306↑18.4% | 258↓12.1% | 294 | |
| Cost of Revenue | 273↑16.9% | 233↑7.7% | 217↑21.5% | 178↑62.5% | 110 | |
| Gross Profit | 539↑201.6% | 179↑100.2% | 89↑11.6% | 80↓56.5% | 184 | |
| Operating Expenses | ||||||
| R&D Expenses | 45↓60.2% | 114↓2.5% | 117↑15.4% | 101 | 0.00 | |
| General & Administrative Expenses | 225↑29.6% | 174↑14.2% | 152↓2.7% | 156↑471.7% | 27 | |
| Selling & Marketing Expenses | 168↑13.0% | 148↑6.3% | 140↑0.8% | 138 | 0.00 | |
| SG&A Expenses | 392↑21.9% | 322↑10.4% | 291↓1.0% | 295↑978.3% | 27 | |
| Other Expenses | 56↑43860.9% | 0.13↓74.4% | 0.50 | 0.00↓100.0% | 18 | |
| Operating Expenses | 494↑13.3% | 436↑6.6% | 409↑3.3% | 396↑778.1% | 45 | |
| Total Costs & Expenses | 767↑14.6% | 669↑7.0% | 626↑9.0% | 574↑270.7% | 155 | |
| Operating Results | ||||||
| Operating Income | 45↑117.5% | -257↑19.5% | -320↓1.2% | -316↓327.0% | 139 | |
| Depreciation & Amortization | 23↓53.8% | 49↓0.2% | 49↑1.6% | 48↓56.4% | 111 | |
| EBITDA | 11↑106.2% | -183↑29.9% | -261↓6.1% | -246↓196.6% | 254 | |
| EBIT | -11↑95.2% | -232↑25.2% | -310↓5.3% | -294↓304.5% | 144 | |
| Interest & Other Income | ||||||
| Net Interest Income | -40↑5.9% | -43↓110.8% | -20↑20.9% | -26↑58.2% | -62 | |
| Interest Income | 16↑131.6% | 7↓36.7% | 11↑1088.8% | 0.95 | 0.00 | |
| Interest Expense | 57↑13.6% | 50↑58.3% | 32↑18.5% | 27↓56.7% | 62 | |
| Non-Operating Income | 56↑323.1% | -25↓159.2% | -10↑54.9% | -22↓357.8% | -5 | |
| Other Income / Expenses | -113↓357.0% | -25↓13.3% | -22↓331.2% | -5↑95.4% | -110 | |
| Income Before Tax | -68↑75.8% | -282↑17.4% | -341↓6.4% | -321↓1186.3% | 30 | |
| Income Tax Expense | 470 | 0.00 | 0.00 | 0.00↓100.0% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -538↓90.8% | -282↑17.4% | -341↓6.4% | -321↓1256.8% | 28 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -538↓90.8% | -282↑17.4% | -341↓6.4% | -321↓1256.8% | 28 | |
| Bottom-Line Net Income | -538↑21.9% | -688↓48.8% | -463↓15.7% | -400↓1541.7% | 28 | |
| EPS (Basic) | -1.90↑29.6% | -2.70↓48.4% | -1.82↓15.9% | -1.57↓201.3% | 1.55 | |
| EPS (Diluted) | -1.90↑29.6% | -2.70↓48.4% | -1.82↓15.9% | -1.57↓201.3% | 1.55 | |
| Weighted Average Shares | 1,672↑556.6% | 255↑0.0% | 255↓0.0% | 255↑1319.5% | 18 | |
| Weighted Average Diluted Shares | 1,672↑556.6% | 255↑0.0% | 255↓0.0% | 255↑1319.5% | 18 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.